Table 2.
Operative details and postoperative outcome of patients with COVID-19
| N = 18 | |
|---|---|
| Operation type | |
| Aortic valve replacement, n | 6 |
| Mitral valve replacement, n | 2 |
| Mitral valve repair, n | 1 |
| Coronary artery bypass grafting, n | 4 |
| Aortic valve replacement, mitral valve repair and coronary artery bypass grafting, n | 1 |
| Aortic valve replacement and coronary artery bypass grafting, n | 1 |
| Aortic valve replacement and ascending aorta replacement, n | 2 |
| Aortic valve replacement, ascending aorta replacement and coronary artery bypass grafting | 1 |
| Cardiopulmonary bypass time, min, median (IQR) | 75.5 (26.7) |
| Crossclamp time, min, median (IQR) | 50.5 (11) |
| Postoperative results | |
| Overall mortality, n (%) | 3 (16.6) |
| Mechanical ventilation time, min, median (IQR) | 7 (7) |
| Postoperative intubation time >24 h, n (%) | 1 (5.5) |
| Respiratory failure (Po2/Fio2 <200) | 2 (11.1) |
| Acute kidney injury 1, n (%) | 8 (44.4) |
| Acute kidney injury 2, n (%) | 2 (11.1) |
| Acute kidney injury 3, n (%) | 3 (16.6) |
| Peak creatinine, mg/dL, median (IQR) | 1.5 (1.05) |
| Use of inotropes/vasopressor, n (%) | 8 (44.4) |
| Number of packed red cells, median (IQR) | 1 (3) |
| Reopening for bleeding, n (%) | 1 (5.5) |
| De novo atrial fibrillation, n (%) | 11 (67.2) |
| Left ventricle ejection fraction, % ± SD | 47.7 ± 19.7 |
| Intensive care unit length of stay, d, median (IQR) | 2 (1.2) |
| In-hospital length of stay, d, median (IQR) | 18 (14) |
Data are presented as mean ± standard deviation (SD) or median and interquartile range (IQR) or number and frequency (%). Acute kidney injury accordingly to RIFLE (Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease) criteria. Po2, Oxygen tension; Fio2, inspired oxygen fraction.